While brokerage consensus suggests potential upside, the "Sell" recommendation from Goldman Sachs warrants close attention as generic competition continues to grow worldwide.
What's New: August 2026 Update TRIUMPH-2 and TRIUMPH-3 confirmed (July 23, 2026): Two additional Phase 3 trials completed obesity + diabetes (20.8% weight loss) and obesity + cardiovascular disease (22.6% weight loss)
However, there still needs to be more research to substantiate this link
It's not a reliable or dramatic whitening agent, and the evidence is still considered inconclusive overall
6 Week Plan Ozempic Weight Loss Results Price: What Youll Actually Pay Cost is one of the biggest factors in whether a 6-week Ozempic plan is even realistic for most patients, and its rarely discussed alongside the results themselves
Pfizer, after discontinuing its initial danuglipron candidate due to safety concerns in April 2025, re-entered the race through a $10 billion acquisition of clinical-stage biotech Metsera in November 2025, securing a next-generation obesity pipeline [43]